Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects

British Journal of Clinical Pharmacology

Volumn 48, Issue 4, 1999, Pages 501-509

  Turnheim, K ^a   Krivanek, P ^b   Oberbauer, R ^b  

^a Pharmakologisches Institut   (Austria)

^b NONE

Author keywords

Allopurinol; Elderly; Oxipurinol; Pharmacodynamics; Pharmacokinetics; Uric acid

Indexed keywords

ALLOPURINOL; DRUG METABOLITE; HYPOXANTHINE; OXIPURINOL; URIC ACID; XANTHINE;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLOPURINOL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; FEMALE; HUMANS; HYPOXANTHINE; MALE; OXYPURINOL; TIME FACTORS; URIC ACID; XANTHINE;

EID: 0032847798     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00041.x     Document Type: Article

References (36)

1. 1 Rundles RW. The development of allopurinol. Arch Intent Med 1985; 145: 1492-1503.
2. 2 Elion GB. The purine path to chemotherapy. Science 1989; 244: 41-47.
3. 3 Day RO, Birkett DJ, Hicks M, Miners JO, Graham GG, Brooks PM. New uses for allopurinol. Drugs 1994; 48: 339-344.
4. 4 Stewart R, Yost R, Hale W, Marks R. Epidemiology of hyperuricemia in an ambulatory elderly population. J Am Geriatr Soc 1979; 27: 552-554.
5. 5 Doherty M, Dieppe P. Crystal deposition disease in the elderly. Clin Rheumatol 1986; 12: 97-116.
6. 6 Fam AG. Gout in the elderly. Clinical presentation and treatment. Drugs Aging 1998; 13: 229-243.
7. 7 Turnheim K. Drug dosage in the elderly: Is it rational? Drugs Aging 1998; 13: 357-379.
8. 8 Wung WE, Howell SB. Simultaneous liquid chromatography of 5-fluorouracil, uridine, hypoxanthine, xanthine, uric acid, allopurinol, and oxipurinol in plasma. Clin Chem 1980; 26: 1704-1708.
9. 9 Dost FH. Grundlagen der Pharmakokinetik, 2. Aufl. Stuttgart: Georg Thieme-Verlag 1968.
10. 10 McLachlan MSF. The aging kidney. Lancet 1978; ii: 143-146.
11. 11 Elion GH. Allopurinol and other inhibitors of urate synthesis. In: Handbook of Experimental Pharmacology, Vol 51: Uric Acid, eds. Kelley WN, Weiner IM, Berlin Heidelberg New York: Springer Verlag, 1978: 485-514.
12. 12 Rowe JW. Clinical research on aging, strategies and directions. N Engl J Med 1977; 297: 1332-1336.
13. 13 Lindeman RD. Renal and urinary tract. In: Handbook of Physiology, Sect 11: Aging. Ed Masoro EJ, New York Oxford: Oxford University Press, 1995: 485-503.
14. 14 Turner N, Scarpace PJ, Lowenthat DT. Geriatric pharmacology: Basic and clinical considerations. Annu Rev Pharmacol Toxicol 1992; 32: 271-302.
15. 15 Mayersohn MB. Special pharmacokinetic considerations in the elderly. In Applied Pharmacokinetics, 3rd edn. eds. Evans WE, Schentag JJ, Jusko WJ, Vancouver, WA. Applied Therapeutic, Inc 1992 9.1-9.43.
16. 16 Hande KR, Noone RM, Stone WJ. Severe allopurinol toxidty. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47-56.
17. 17 Elion GH, Kovensky A, Hitchings GH, Metz E, Rundles RW. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol 1966; 15: 863-880.
18. 18 Breithaupt H, Tittel M. Kinetics of allopurinol after single intravenous and oral dose. Noninteraction with benzbromarone and hydrochlorothiazide. Eur J Clin Pharmacol 1982; 22: 77-84.
19. 19 Graham S, Day RO, Wong H, et al. Pharmacodynamics of oxipurinol after administration of allopurinol to healthy subjects. Br J Clin Pharmacol 1996; 41: 299-304.
20. 20 Appelbaum SJ, Mayersohn M, Dorr RT, Perrier D. Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration. Cancer Chemother Pharmacol 1982; 8: 93-98.
21. 21 Colin JN, Farinotti R, Fredj G, Clavel JP, Vignon E, Dietlin F. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interactions with benzbromarone. Eur J Clin Pharmacol 1986; 31: 53-58.
22. 22 Walter Sack I, de Vries JX, Kutschker C, Ittensohn A, Voss A. Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals. Eur J Clin Pharmacol 1995; 49: 215-220.
23. 23 Van Remmen H, Ward WE, Sabia RV, Richardson A. Gene expression and protein degradation. In: Handbook of Physiology, Section 11: Aging. Ed Masoro EJ, New York Oxford: Oxford University Press, 1995: 171-234.
24. 24 Gafni A. Structural modifications of proteins during aging. J Am Geriatr Soc 1997; 45: 871-880.
25. 25 Haining JL, Legan JS, Lovell WJ. Synthesis and degradation of rat liver xanthine oxidase as a function of age and protein deprivation. J Gerontol 1970; 25: 205-209.
26. 1). J Biol Chem 1993; 268: 20085-20090.
27. 27 Akerman R, Jarvis SM. Nucleobase transport in cultured renal epithelial cells. Biochem Soc Trans 1995; 23: 29S.
28. 28 Plagemann PGW, Wohlhueter RM, Wolffendin C. Nucleoside and nucleobase transport in animal cells. Biochim Biophys Acta 1988; 947: 405-443.
29. 29 Kraupp M, Marz R. Membrane transport of nucleobases: Interactions with inhibitors. Gen Pharmacol 1995; 26: 1185-1190.
30. 30 Razavi M, Kraupp M, Marz R. Allopurinol transport in human erythrocytes. Biochem Pharmacol 1993; 45: 893-897.
31. 31 Löffler W, Seibke W, Seibke E, et al. Non-responsiveness to allopurinol in renal hypouricaemia. Klin Wochenschr 1989; 67: 47.
32. 32 Elion GB, Yü TF, Gutman AB, Hitchings GH. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med 1968; 45: 69-77.
33. 33 Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Yamakita J, Higashino K. Difference in the plasma concentration and urinary excretion of allopurinol, oxypurinol, and purine bases between dietary intake and fasting. Int J Clin Pharmacol Ther 1996; 34: 157-162.
34. 34 Cameron JS, Simmonds HA. Use and abuse of allopurinol. Br Med J 1987; 294: 1504-1505.
35. 35 Peterson GM, Boyle RR, Francis HW, et al. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy. Eur J Clin Pharmacol 1990; 39: 419-421.
36. 36 Conaghan PG, Day RO. Risks and benefits of drugs used in the management and prevention of gout. Drug Safety 1994; 11:252-258.